ADMA Biologics stock drops over 21% after FDA competition and pricing concerns hit Q1 results.

ADMA Biologics reported that new FDA-approved IVIG products with aggressive pricing tactics have increased competition, impacting its first quarter 2026 results, especially for its BIVIGAM product. This competitive pressure has led to a sharp decline in ADMA's stock price by more than 21% in pre-market trading. Additionally, a March 2026 report accused ADMA of inflating growth through questionable distribution practices. Investors are being advised to consider potential legal claims as investigations are underway.